Lipodystrophy Pipeline Insight

DelveInsight’s, “Lipodystrophy – Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Lipodystrophy Understanding

Lipodystrophy: Overview

Lipodystrophy refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at birth (congenital). There are five types of lipodystrophy: Congenital generalized lipodystrophy, acquired generalized lipodystrophy, Acquired partial lipodystrophy, High active antiretroviral therapy-induced lipodystrophy, and Localized lipodystrophy. The specific symptoms present, severity, and prognosis can vary greatly depending upon the specific type of lipodystrophy and the presence and extent of associated symptoms. To make the medical diagnosis of lipodystrophy the doctor first examine the abnormal appearance caused by changes in fat loss or gain, and then he or she generally look for the characteristic clinical symptoms and signs.


Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lipodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Lipodystrophy.

Lipodystrophy Emerging Drugs Chapters

This segment of the Lipodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Lipodystrophy Emerging Drugs


Vupanorsen: Ionis Pharmaceuticals/Pfizer

Vupanorsen, formerly known as IONIS-ANGPTL3-LRx and AKCEA-ANGPTL3-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce angiopoietin-like 3 protein, or ANGPTL3. Human genetic studies have shown that lower levels of ANGPTL3 are associated with lower plasma triglyceride (TG) and LDL-C and protection against certain cardiovascular diseases1,3-4. Studies in animals have demonstrated that targeted reduction of ANGPTL3 with antisense drugs results in substantially decreased TG and LDL-C2. A large number of patients with elevated risk of cardiovascular disease are not reaching recommended TG and LDL-C goals. Vupanorsen is being developed to reduce plasma levels of ANGPTL3 with the goal of lowering levels of plasma TG and LDL-C to potentially reduce the risk of future cardiovascular events. In October 2019, Akcea therapeutics and Pfizer entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx. A Phase II clinical study evaluating AKCEA-ANGPTL3-LRx for the treatment of Familial Partial Lipodystrophy has been completed.


REGN4461: Regeneron Pharmaceuticals

REGN4461 is a leptin receptor (LEPR) agonist for lipodystrophy and obesity which is being developed by Regeneron Pharmaceuticals. It is currently in the Phase II stage of development. It is administered intravenously or subcutaneously.

Further product details are provided in the report……..

Lipodystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Lipodystrophy drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Lipodystrophy

There are approx. 10+ key companies which are developing the therapies for Lipodystrophy. The companies which have their Lipodystrophy drug candidates in the most advanced stage, i.e. Phase III include,Ionis Pharmaceuticals/Pfizer.


DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Lipodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lipodystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipodystrophy therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipodystrophy drugs.

Lipodystrophy Report Insights

  • Lipodystrophy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Lipodystrophy Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Lipodystrophy drugs?
  • How many Lipodystrophy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lipodystrophy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipodystrophy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lipodystrophy and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Lipodystrophy: Overview

  • Causes
  • Mechanism of Action 
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

Lipodystrophy – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Lipodystrophy companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Lipodystrophy Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II) 

  • Comparative Analysis

Vupanorsen: Ionis Pharmaceuticals/Pfizer

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Preclinical stage products

  • Comparative Analysis

CGT2: CombiGene

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Lipodystrophy Key Companies

Lipodystrophy Key Products

Lipodystrophy- Unmet Needs

Lipodystrophy- Market Drivers and Barriers

Lipodystrophy- Future Perspectives and Conclusion

Lipodystrophy Analyst Views

Lipodystrophy Key Companies


List of Table

Table 1: Total Products for Lipodystrophy

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Lipodystrophy

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Regeneron Pharmaceuticals
• Ionis Pharmaceuticals
• Pfizer
• Galmed Pharmaceuticals
• CombiGene
• Cell Praxis
• Zydus Cadila
• Carmot Therapeutics
• Lipigon Pharmaceuticals


Forward to Friend

Need A Quote